Literature DB >> 12199847

Do multiple blood transfusions predispose for a higher rate of non-blood-related infection complications?

S R Leal Noval, I Jara López.   

Abstract

Allogeneic transfusions of red blood cell (RBC) concentrates have been related to an increase in postoperative infections. Leukocytes present in RBC units might have deleterious effects on the receptor immune system, provoking a state of immunosuppression that favors the development of postoperative infections (TRIM effect). The bioactive substances released by leukocytes in a time-dependent form, accumulating in blood components during storage, might be responsible for the TRIM effect. Multiple observational studies with logistic regression have demonstrated a direct relationship between transfusion and infection. However, several factors related to surgical difficulty and patient illness severity might act as strong confounding variables on the relationship studied. Randomized controlled trials designed to establish a causal relationship between transfusion and infection have yielded contradictory results. While we await new studies, allogeneic transfusions should be considered as a possible risk factor for postoperative infection.

Entities:  

Mesh:

Year:  2002        PMID: 12199847     DOI: 10.1046/j.1469-0691.2002.00465.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  2 in total

1.  Duration of red blood cell storage and outcomes in pediatric cardiac surgery: an association found for pump prime blood.

Authors:  Marco Ranucci; Concetta Carlucci; Giuseppe Isgrò; Alessandra Boncilli; Donatella De Benedetti; Teresa De la Torre; Simonetta Brozzi; Alessandro Frigiola
Journal:  Crit Care       Date:  2009-12-21       Impact factor: 9.097

2.  The impact of two different transfusion strategies on patient immune response during major abdominal surgery: a preliminary report.

Authors:  Kassiani Theodoraki; Maria Markatou; Demetrios Rizos; Argyro Fassoulaki
Journal:  J Immunol Res       Date:  2014-04-03       Impact factor: 4.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.